# Briefing Paper for Meeting between the EU and the US on the Status of the WTO Biotechnology Case

### Insect biotechnology in the United States and the EU

## **Talking Points**

#### GE Insects

• The olive fly is responsible for considerable damage to olive production in Europe, especially this last year. Is the EU considering the use of GE insects to control this pest in the future? Are there any GE insects (e.g., Mosquitos, Olive flies, or Medflies) currently under review in the EU, either for approval or caged trials?

# [Only if asked:]

### GE Mosquito:

- FDA released a final environmental assessment (EA) on the potential environmental impacts of conducting a proposed field trial of Oxitec's GE *Aedes aegypti* mosquito in Key Haven, FL and a final finding of no significant impact (FONSI) agreeing with the EA's conclusion that the proposed field trial would not have significant impacts on the environment.
- No trial releases of this GE mosquito (intended to control mosquitos which may carry human disease causing agents such as Zika and dengue) have yet occurred in the United States.
- On January 19, 2017, FDA released a Draft Guidance for Industry (GFI) #236, Regulation of Mosquito-Related Products stating that mosquito-related products intended to function as pesticides by preventing, destroying, repelling, or mitigating mosquitoes for population control purposes are not "drugs" under the FD&C Act, and, when the guidance is finalized, will be regulated by EPA under FIFRA.

#### GE Pink Bollworm:

- In 2006, APHIS BRS completed an environmental assessment and issued a permit for field trials of pink bollworm genetically engineered to express green fluorescence as a marker.
- Since then, field trials have occurred under APHIS BRS permits using pink bollworms genetically engineered to express red or green fluorescence proteins.

#### GE Diamondback Moth:

- USDA/APHIS published a draft EA for public comment for the Oxitec Diamondback Moth in August 2014. Following APHIS' analysis of the public comments received on the EA, APHIS revised its EA and prepared a Finding of No Significant Impact (FONSI). These documents, the final EA and FONSI, were posted on APHIS' web page in November 2014. Due to a clerical issue, the EA and FONSI have been withdrawn, Cornell University has resubmitted an application and APHIS BRS is currently reviewing the new permit application.
- Only caged field releases of GE diamondback moths have occurred.

# Briefing Paper for Meeting between the EU and the US on the Status of the WTO Biotechnology Case

### Background

Oxitec, a British company now wholly owned by an American company, Intrexon, has developed GE insects for population suppression of the same species in the wild based on a genetic sterile insect technique that is currently undergoing regulatory review in the United States (and other countries). The goal for this technology is to reduce the local target insect population by the release of conditionally lethal GE males of the same species that mate with wild females. The GE males do produce sperm which can fertilize the female's eggs; however, the resulting hemizygous offspring will inherit the self-limiting gene from the homozygous GE male parent and will die before reaching adulthood. In some implementations (Oxitec GE mosquito), offspring of both sexes will die before reaching adulthood, whereas in other implementations (e.g. diamondback moth) only female offspring will die. The same technology is used to control insects for and agricultural purposes.

Regulation of GE Insects in the United States: EPA, FDA and USDA will continue to examine their regulatory structures with the goal of clarifying how the U.S. Federal Government will regulate genetically engineered insects in an integrated and coordinated fashion to cover the full range of potential products. The characteristics or intended use of the GE insect determines which agency(ies) has jurisdiction for its regulation. APHIS-BRS regulations govern GE insects that are plant pests (i.e. harm or damage plants or plant products). When FDA's draft Guidance For Industry #236 is finalized, EPA will regulate mosquito-related products intended to reduce the population of mosquitoes and FDA will regulate such products with other claims such as those intended to reduce the virus/pathogen load within a mosquito and also products that claim to prevent mosquito-borne disease in humans or animals. FDA's Center for Veterinary Medicine (FDA-CVM) has said it will not regulate GE insects that are regulated by another U.S. government agency, such as those that are regulated by APHIS-BRS or EPA under their regulations. [also see Briefing Paper on "Modernizing the U.S. regulatory system for biotechnology products".]

For insect plant pests, such as strains of Oxitec's GE diamondback moth (a pest of cruciferous crops, such as cabbage) and Oxitec's GE pink bollworm, the Animal and Plant Health Inspection Service (APHIS), pursuant to the Plant Protection Act of 2000, regulates genetically engineered plant pests under its regulations at 7 CFR part 340. In response to a permit application from Cornell University for field release of an Oxitec strain of GE diamondback moth, APHIS BRS posted to its web site its final environmental assessment and FONSI for this GE moth in November 2014. However, while APHIS reached a finding of no significant impact (FONSI) in connection with this permitted release and posted that FONSI on their Web site, the public was not notified via a second notice in the Federal Register. Therefore, APHIS/BRS withdrew the EA and FONSI associated with the notice (notice of withdrawal was posted November 2016). At this point, only caged field releases of GE diamond back moths have occurred. Cornell University withdrew its permit application in March 2016 (see above) and reapplied shortly thereafter. APHIS BRS is currently reviewing the new permit application for field release of the Oxitec strain of GE diamondback moth.

In 2006, APHIS BRS completed an environmental assessment and issued a permit to an APHIS researcher for field trials using an Oxitec strain of pink bollworm genetically engineered to

# Briefing Paper for Meeting between the EU and the US on the Status of the WTO Biotechnology Case

express green fluorescence as a marker. Between 2006 and 2016, the permittee has conducted field trials under APHIS BRS permits using pink bollworms genetically engineered to express red or green fluorescence proteins as a marker.

In addition to the diamondback moth and pink bollworm, Oxitec has produced a number of GE insects for the control of insect plant pests, including the Olive Fly, Medfly (an Oxitec GE Medfly is approved for field trials in Brazil), and Mexfly. [NB: The Oxitec GE olive fly that is in development is targeted at the European olive industry (e.g., Spain).]

GE mosquito: FDA released a final environmental assessment (EA) on the potential environmental impacts of conducting a proposed field trial of Oxitec's GE Aedes aegypti mosquito in Key Haven, FL and a final finding of no significant impact (FONSI) agreeing with the EA's conclusion that the proposed field trial would not have significant impacts on the environment. This EA and FONSI conclusion applies to the proposed release in Key Haven, FL only and would not cover any other potential release sites.

In November 2016, residents in the Florida Keys voted in a non-binding referendum on whether to support investigational releases of Oxitec's GE mosquito. Voters in Key Haven, the proposed trial site, voted against the releases while voters in the rest of the Keys (Monroe country) voted in favor of the releases. Following the vote, the local mosquito control district said that it would not go forward with the Key Haven release. It is up to the mosquito control district and Oxitec whether they will seek to conduct a release elsewhere. No releases of GE mosquitos have yet occurred in the United States.

In April 2016, this GE mosquito received a special temporary registration from the National Health Surveillance Agency of Brazil (ANVISA). In 2014 the National Technical Commission of Biosecurity (CTNBio) found the Oxitec mosquito safe to use in Brazil.

Drafted by: Diane Wray-Cahen, USDA/FAS/NTPMD, 202-690-3324, February 16, 2017

Cleared by: FDA/CVM, Laura Epstein, February 17, 2017 Cleared by: USDA/APHIS, Alan Pearson, February 17, 2017 Cleared by: EPA, Elizabeth Milewski, February 17, 2017